Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program

- May 8th, 2018

Immuron (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, is today pleased to announce the successful completion of its colitis preclinical program at the University of Zürich, Switzerland. As quoted in the press release: Immuron is pleased … Continued

Immuron (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, is today pleased to announce the successful completion of its colitis preclinical program at the University of Zürich, Switzerland.

As quoted in the press release:

Immuron is pleased to report that oral administration of IMM-124E was successfully able to treat mice with immunologically induced colitis. The University of Zürich research revealed that IMM-124E offered a significant therapeutic benefit on clinically meaningful study parameters.

In contrast to the results reported in April 2017 using an acute colitis model the latest results were generated in the T cell transfer model which utilizes immunodeficient mice which are deficient in functional B and T lymphocytes. In this model chronic colitis is induced immunologically not chemically. IMM-124E was administered orally after the onset of colitis symptoms such as weight loss and macroscopically inflamed colon were confirmed by colonoscopy prior to the initiation of treatment.

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply